Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Recruiting 2Active not recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 33Gastrointestinal 28CNS 23Genitourinary 17Dermatologic 11Head & Neck 9Breast 6Sarcoma 4Other solid neoplasm 3Tumor-Agnostic 2Other neoplasm 1Gynecologic 1Endocrine 1

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Radiosurgery × Gynecologic × Clear all
NCT01494012 2017-04-28

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Stanford University

Phase 1 Terminated
1 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡